Cereno’s CS1 Shows Promising Results in Reducing PAH Risks in Phase 2 Trial
Cereno Scientific, CS1, HDAC inhibitor, Pulmonary Arterial Hypertension (PAH), Phase 2 trial, Epigenetic modulation, CardioMEMS HF System, Disease-modifying treatment
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Manipulated Alzheimer’s Trial Data
Cassava Sciences, SEC charges, Alzheimer’s drug, simufilam, manipulated trial data, settlement, misleading statements
Roche’s Gazyva Shows Promising Results in Phase 3 Lupus Nephritis Trial, Paving Way for Expanded Use
Gazyva, lupus nephritis, Roche, phase 3 trial, REGENCY study, obinutuzumab, kidney disease, autoimmune disease, treatment options.
Bristol Myers Squibb’s $14 Billion Bet Pays Off: FDA Approves Novel Schizophrenia Drug Cobenfy
Bristol Myers Squibb, Karuna Therapeutics, FDA approval, schizophrenia, Cobenfy, novel treatment, muscarinic receptor, psychiatric medication
Gazyva Shows Promising Results in Lupus Nephritis Treatment, Paving Way for Expanded Indication
Gazyva, lupus nephritis, Roche, Genentech, Phase III REGENCY study, complete renal response, autoimmune disease, kidney function, end-stage kidney disease.
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Misleading Alzheimer’s Drug Trial Claims
Cassava Sciences, SEC settlement, Alzheimer’s drug trial, misleading claims, data manipulation, simufilam, pharmaceutical fraud
Sanofi and Regeneron’s Dupixent Secures Historic FDA Approval as First Biologic Treatment for COPD
Dupixent, COPD, FDA Approval, Biologic Treatment, Sanofi, Regeneron
FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression
PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab
AbbVie’s Tavapadon Shows Promising Results in Phase III Trial for Parkinson’s Disease
AbbVie, Tavapadon, Parkinson’s Disease, Phase III Trial, TEMPO-1, Cerevel Therapeutics
FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression
FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval